Hematological Toxicity in Mice after High Activity Injections of ¹⁷⁷Lu-PSMA-617

Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., ¹⁷⁷Lu-PSMA-617, has been effecti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, Joanna Strand, Sven-Erik Strand, Bo Åkerström, Anders Örbom
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-03-01
Edice:	Pharmaceutics
Témata:	radioligand therapy <sup>177</sup>Lu-PSMA-617 prostate cancer mouse model hematotoxicity
On-line přístup:	https://www.mdpi.com/1999-4923/14/4/731
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!